Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 74 articles:
HTML format
Text format



Single Articles


    September 2019
  1. VISSER S, Koolen SLW, de Bruijn P, Belderbos HNA, et al
    Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study.
    Eur J Cancer. 2019;121:64-73.
    PubMed     Text format     Abstract available


  2. DE JONG EEC, Sanders KJC, Deist TM, van Elmpt W, et al
    Can radiomics help to predict skeletal muscle response to chemotherapy in stage IV non-small cell lung cancer?
    Eur J Cancer. 2019;120:107-113.
    PubMed     Text format     Abstract available


  3. LEE SM, Upadhyay S, Lewanski C, Falk S, et al
    The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
    Eur J Cancer. 2019;120:86-96.
    PubMed     Text format     Abstract available


    August 2019
  4. YUAN P, Huang S, Bao FC, Cao JL, et al
    Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation.
    Eur J Cancer. 2019;120:10-19.
    PubMed     Text format     Abstract available


  5. MAK DWS, Li S, Minchom A
    Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
    Eur J Cancer. 2019;119:132-150.
    PubMed     Text format     Abstract available


  6. CHANG LC, Lim CK, Chang LY, Chen KY, et al
    Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Eur J Cancer. 2019;119:77-86.
    PubMed     Text format     Abstract available


  7. YAO ZH, Liao WY, Ho CC, Chen KY, et al
    Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.
    Eur J Cancer. 2019;117:107-115.
    PubMed     Text format     Abstract available


    July 2019
  8. PASTORINO U, Sverzellati N, Sestini S, Silva M, et al
    Ten-year results of the Multicentric Italian Lung Detection trial demonstrate the safety and efficacy of biennial lung cancer screening.
    Eur J Cancer. 2019;118:142-148.
    PubMed     Text format     Abstract available


  9. GEZELIUS E, Bendahl PO, Goncalves de Oliveira K, Ek L, et al
    Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN).
    Eur J Cancer. 2019;118:82-90.
    PubMed     Text format     Abstract available


  10. ARFFMAN M, Manderbacka K, Suvisaari J, Koivunen J, et al
    The impact of severe mental illness on lung cancer mortality of patients with lung cancer in Finland in 1990-2013: a register-based cohort study.
    Eur J Cancer. 2019;118:105-111.
    PubMed     Text format     Abstract available


    June 2019
  11. LINDSAY CR, Blackhall FH, Carmel A, Fernandez-Gutierrez F, et al
    EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.
    Eur J Cancer. 2019;117:60-68.
    PubMed     Text format     Abstract available


  12. HENDRIKS LEL, Bootsma G, Mourlanette J, Henon C, et al
    Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
    Eur J Cancer. 2019;116:182-189.
    PubMed     Text format     Abstract available


  13. RECK M, Schenker M, Lee KH, Provencio M, et al
    Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial.
    Eur J Cancer. 2019;116:137-147.
    PubMed     Text format     Abstract available


  14. COURAUD S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, et al
    Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
    Eur J Cancer. 2019;116:86-97.
    PubMed     Text format     Abstract available


    May 2019
  15. FOUCHARD M, Jantzem H, Quere G, Descourt R, et al
    Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.
    Eur J Cancer. 2019;115:107-110.
    PubMed     Text format    


  16. SCHOENMAEKERS J, Hofman P, Bootsma G, Westenend M, et al
    Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study.
    Eur J Cancer. 2019;115:88-96.
    PubMed     Text format     Abstract available


    April 2019
  17. MCGOWAN DR, Skwarski M, Bradley KM, Campo L, et al
    Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
    Eur J Cancer. 2019;113:87-95.
    PubMed     Text format     Abstract available


    February 2019
  18. RATHOD S, Jeremic B, Dubey A, Giuliani M, et al
    Role of thoracic consolidation radiation in extensive stage small cell lung cancer: A systematic review and meta-analysis of randomised controlled trials.
    Eur J Cancer. 2019;110:110-119.
    PubMed     Text format     Abstract available


  19. WANG Z, Huang C, Yang JJ, Song Y, et al
    A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).
    Eur J Cancer. 2019;109:183-191.
    PubMed     Text format     Abstract available


    January 2019
  20. LEVY BP, Giaccone G, Besse B, Felip E, et al
    Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
    Eur J Cancer. 2019;108:120-128.
    PubMed     Text format     Abstract available


  21. BASAK EA, Koolen SLW, Hurkmans DP, Schreurs MWJ, et al
    Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
    Eur J Cancer. 2019;109:12-20.
    PubMed     Text format     Abstract available


  22. CHARRIER M, Mezquita L, Lueza B, Dupraz L, et al
    Circulating innate immune markers and outcomes in treatment-naive advanced non-small cell lung cancer patients.
    Eur J Cancer. 2019;108:88-96.
    PubMed     Text format     Abstract available


    December 2018
  23. VON PAWEL J, Bordoni R, Satouchi M, Fehrenbacher L, et al
    Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
    Eur J Cancer. 2018;107:124-132.
    PubMed     Text format     Abstract available


  24. PRELAJ A, Tay R, Ferrara R, Chaput N, et al
    Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.
    Eur J Cancer. 2018;106:144-159.
    PubMed     Text format     Abstract available


    October 2018
  25. WIJN DH, Groeneveld GH, Vollaard AM, Muller M, et al
    Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
    Eur J Cancer. 2018;104:182-187.
    PubMed     Text format     Abstract available


    September 2018
  26. JONES GS, McKeever TM, Hubbard RB, Khakwani A, et al
    Factors influencing treatment selection and 30-day mortality after chemotherapy for people with small-cell lung cancer: An analysis of national audit data.
    Eur J Cancer. 2018;103:176-183.
    PubMed     Text format     Abstract available


    August 2018
  27. RECK M, Brahmer J, Bennett B, Taylor F, et al
    Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
    Eur J Cancer. 2018;102:23-30.
    PubMed     Text format     Abstract available


  28. HORN L, Gettinger SN, Gordon MS, Herbst RS, et al
    Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
    Eur J Cancer. 2018;101:201-209.
    PubMed     Text format     Abstract available


  29. BONANNO L, Pavan A, Dieci MV, Di Liso E, et al
    The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
    Eur J Cancer. 2018;101:191-200.
    PubMed     Text format     Abstract available


  30. GANTENBEIN N, Bernhart E, Anders I, Golob-Schwarzl N, et al
    Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression.
    Eur J Cancer. 2018;101:165-180.
    PubMed     Text format     Abstract available


    July 2018
  31. LIU SV, Camidge DR, Gettinger SN, Giaccone G, et al
    Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.
    Eur J Cancer. 2018;101:114-122.
    PubMed     Text format     Abstract available


  32. DETILLON DDEMA, Driessen EJM, Aarts MJ, Janssen-Heijnen MLG, et al
    Changes in treatment patterns and survival in elderly patients with stage I non-small-cell lung cancer with the introduction of stereotactic body radiotherapy and video-assisted thoracic surgery.
    Eur J Cancer. 2018;101:30-37.
    PubMed     Text format     Abstract available


  33. GROSSI F, Crino L, Logroscino A, Canova S, et al
    Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
    Eur J Cancer. 2018;100:126-134.
    PubMed     Text format     Abstract available


    June 2018
  34. LINDSAY CR, Jamal-Hanjani M, Forster M, Blackhall F, et al
    KRAS: Reasons for optimism in lung cancer.
    Eur J Cancer. 2018;99:20-27.
    PubMed     Text format     Abstract available


    May 2018
  35. TAKENAKA T, Kawai Y, Amano T
    Immune checkpoint therapy in proteinuric kidney disease.
    Eur J Cancer. 2018;95:120-122.
    PubMed     Text format    


    April 2018
  36. PRADERE P, Boutros C, Scoazec JY, Dorfmuller P, et al
    Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?
    Eur J Cancer. 2018;93:144-146.
    PubMed     Text format    


    March 2018
  37. DALL'OLIO FG, Brocchi S, Massucci M, Sperandi F, et al
    Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?
    Eur J Cancer. 2018 Mar 21. pii: S0959-8049(18)30227.
    PubMed     Text format    


  38. SCHIEFER M, Hendriks LEL, Dinh T, Lalji U, et al
    Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.
    Eur J Cancer. 2018;91:92-98.
    PubMed     Text format     Abstract available


    February 2018
  39. LEVY A, Faivre-Finn C, Hasan B, De Maio E, et al
    Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.
    Eur J Cancer. 2018;93:37-46.
    PubMed     Text format     Abstract available


    January 2018
  40. SNEE M
    Quality of life comparing carboplatin with cisplatin in the treatment of non-small cell lung cancer.
    Eur J Cancer. 2018 Jan 2. pii: S0959-8049(17)31427.
    PubMed     Text format    


  41. TAZDAIT M, Mezquita L, Lahmar J, Ferrara R, et al
    Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria.
    Eur J Cancer. 2018;88:38-47.
    PubMed     Text format     Abstract available


    December 2017
  42. ANGEVIN E, Spitaleri G, Rodon J, Dotti K, et al
    A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
    Eur J Cancer. 2017;87:131-139.
    PubMed     Text format     Abstract available


    November 2017
  43. KINOSHITA T, Kudo-Saito C, Muramatsu R, Fujita T, et al
    Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
    Eur J Cancer. 2017;86:15-27.
    PubMed     Text format     Abstract available


    October 2017
  44. IIJIMA Y, Hirotsu Y, Amemiya K, Ooka Y, et al
    Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
    Eur J Cancer. 2017;86:349-357.
    PubMed     Text format     Abstract available


  45. SORIA JC, Adjei AA, Bahleda R, Besse B, et al
    A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced n
    Eur J Cancer. 2017;86:186-196.
    PubMed     Text format     Abstract available


  46. DE LA PENA H, Sharma A, Glicksman C, Joseph J, et al
    No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer.
    Eur J Cancer. 2017;84:354-359.
    PubMed     Text format     Abstract available


  47. SHI Y, Lin P, Ho EY, Nock CJ, et al
    Nivolumab-associated nausea and vomiting as an immune adverse event.
    Eur J Cancer. 2017;84:367-369.
    PubMed     Text format    


    September 2017
  48. MAHJOUBI L, Gazzah A, Marabelle A, Le Roy Ladurie F, et al
    Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.
    Eur J Cancer. 2017 Sep 13. pii: S0959-8049(17)31197.
    PubMed     Text format    


  49. MCWILLIAM A, Kennedy J, Hodgson C, Vasquez Osorio E, et al
    Radiation dose to heart base linked with poorer survival in lung cancer patients.
    Eur J Cancer. 2017;85:106-113.
    PubMed     Text format     Abstract available


  50. LIN PL, Wu TC, Wu DW, Wang L, et al
    An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Eur J Cancer. 2017;85:95-105.
    PubMed     Text format     Abstract available


    August 2017
  51. LI F, Zhu T, Cao B, Wang J, et al
    Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Eur J Cancer. 2017;84:184-192.
    PubMed     Text format     Abstract available


  52. JIANG T, Ren S, Li X, Su C, et al
    The changing diagnostic pathway for lung cancer patients in Shanghai, China.
    Eur J Cancer. 2017;84:168-172.
    PubMed     Text format     Abstract available


  53. CUFARI ME, Proli C, De Sousa P, Raubenheimer H, et al
    Increasing frequency of non-smoking lung cancer: Presentation of patients with early disease to a tertiary institution in the UK.
    Eur J Cancer. 2017;84:55-59.
    PubMed     Text format     Abstract available


  54. FERRY D, Billingham L, Jarrett H, Dunlop D, et al
    Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial.
    Eur J Cancer. 2017;83:302-312.
    PubMed     Text format     Abstract available


    July 2017
  55. SU C, Zhou F, Shen J, Zhao J, et al
    Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challen
    Eur J Cancer. 2017;83:266-278.
    PubMed     Text format     Abstract available


  56. SABRKHANY S, Kuijpers MJE, van Kuijk SMJ, Sanders L, et al
    A combination of platelet features allows detection of early-stage cancer.
    Eur J Cancer. 2017;80:5-13.
    PubMed     Text format     Abstract available


  57. MICHOT JM, Vargaftig J, Leduc C, Quere G, et al
    Immune-related bone marrow failure following anti-PD1 therapy.
    Eur J Cancer. 2017;80:1-4.
    PubMed     Text format    


    June 2017
  58. GANDHI L, Ignatius Ou SH, Shaw AT, Barlesi F, et al
    Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
    Eur J Cancer. 2017;82:27-33.
    PubMed     Text format     Abstract available


  59. BERNABE R, Hickson N, Wallace A, Blackhall FH, et al
    What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?
    Eur J Cancer. 2017;81:66-73.
    PubMed     Text format     Abstract available


  60. DEVIC P, Amini-Adle M, Camdessanche JP, Dalle S, et al
    Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors.
    Eur J Cancer. 2017;78:103-104.
    PubMed     Text format    


    May 2017
  61. BRIGHENTI M, Petrelli F, Barni S, Conti B, et al
    Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?
    Eur J Cancer. 2017;79:149-151.
    PubMed     Text format     Abstract available


  62. PASTORINO U, Morelli D, Leuzzi G, Gisabella M, et al
    Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer.
    Eur J Cancer. 2017;79:90-97.
    PubMed     Text format     Abstract available


  63. DE JONGE M, de Weger VA, Dickson MA, Langenberg M, et al
    A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
    Eur J Cancer. 2017;76:144-151.
    PubMed     Text format     Abstract available


  64. PALMERINI E, Chawla NS, Ferrari S, Sudan M, et al
    Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?
    Eur J Cancer. 2017;76:118-124.
    PubMed     Text format     Abstract available


  65. RAVAUD A, de la Fouchardiere C, Caron P, Doussau A, et al
    A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
    Eur J Cancer. 2017;76:110-117.
    PubMed     Text format     Abstract available


  66. ZSCHABITZ S, Lasitschka F, Hadaschik B, Hofheinz RD, et al
    Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Eur J Cancer. 2017;76:1-7.
    PubMed     Text format     Abstract available


    April 2017
  67. GIROUX LEPRIEUR E, Dumenil C, Julie C, Giraud V, et al
    Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Eur J Cancer. 2017;78:16-23.
    PubMed     Text format     Abstract available


  68. SULLIVAN I, Le Teuff G, Guigay J, Caramella C, et al
    Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.
    Eur J Cancer. 2017;75:259-267.
    PubMed     Text format     Abstract available


  69. KIM S, Koh J, Kwon D, Keam B, et al
    Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.
    Eur J Cancer. 2017;75:141-149.
    PubMed     Text format     Abstract available


  70. PRADERE P, Michot JM, Champiat S, Danlos FX, et al
    Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy.
    Eur J Cancer. 2017;75:308-309.
    PubMed     Text format    


    March 2017
  71. TWELVES C, Cortes J, O'Shaughnessy J, Awada A, et al
    Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
    Eur J Cancer. 2017;76:205-215.
    PubMed     Text format     Abstract available


  72. LEONE JP, Leone J, Zwenger AO, Iturbe J, et al
    Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
    Eur J Cancer. 2017;74:17-25.
    PubMed     Text format     Abstract available


    February 2017
  73. DE BAERE T, Tselikas L, Yevich S, Boige V, et al
    The role of image-guided therapy in the management of colorectal cancer metastatic disease.
    Eur J Cancer. 2017;75:231-242.
    PubMed     Text format     Abstract available


  74. SCHAFFAR R, Rachet B, Belot A, Woods LM, et al
    Estimation of net survival for cancer patients: Relative survival setting more robust to some assumption violations than cause-specific setting, a sensitivity analysis on empirical data.
    Eur J Cancer. 2017;72:78-83.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: